Glaukos Co. (NYSE:GKOS) Holdings Increased by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. raised its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 59.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,132 shares of the medical instruments supplier's stock after acquiring an additional 14,593 shares during the quarter. Harbor Capital Advisors Inc. owned approximately 0.07% of Glaukos worth $3,851,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC boosted its stake in shares of Glaukos by 3,957.1% during the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 277 shares during the last quarter. IFP Advisors Inc purchased a new position in Glaukos in the 4th quarter valued at about $43,000. Versant Capital Management Inc boosted its stake in shares of Glaukos by 583.9% during the 1st quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier's stock worth $38,000 after purchasing an additional 327 shares during the last quarter. Asset Planning Inc purchased a new stake in shares of Glaukos during the fourth quarter worth about $90,000. Finally, CoreCap Advisors LLC grew its holdings in shares of Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after buying an additional 200 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Glaukos Stock Performance

Glaukos stock traded up $0.09 during mid-day trading on Friday, reaching $97.69. The company's stock had a trading volume of 797,572 shares, compared to its average volume of 726,788. The firm has a market cap of $5.58 billion, a price-to-earnings ratio of -34.04 and a beta of 0.80. Glaukos Co. has a twelve month low of $77.10 and a twelve month high of $163.71. The business has a 50 day moving average price of $92.76 and a 200-day moving average price of $119.82. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. The business had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company's quarterly revenue was up 24.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.70) EPS. Sell-side analysts predict that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on GKOS shares. Wells Fargo & Company lowered Glaukos from an "overweight" rating to an "equal weight" rating and decreased their price target for the stock from $160.00 to $86.00 in a research note on Thursday, May 1st. Stifel Nicolaus decreased their price objective on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Needham & Company LLC lowered their target price on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Stephens dropped their target price on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. Finally, Morgan Stanley reduced their price target on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat.com, Glaukos has a consensus rating of "Moderate Buy" and an average price target of $134.67.

Insider Activity at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 1,520 shares of the company's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 5.80% of the company's stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.